Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: Preventive and therapeutic implications

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 147-164

  Suba, Zsuzsanna ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Cancer prevention; Infertility; Insulin resistance; Menopause; Metabolic syndrome; Type 2 diabetes

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

AFRICAN AMERICAN; ARTICLE; BRCA 1 GENE; BRCA 2 GENE; CANCER INCIDENCE; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CLINICAL FEATURE; EUROPEAN AMERICAN; FEMALE; GENE; GENE MUTATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PARITY; POSTMENOPAUSE; RISK FACTOR; TRIPLE NEGATIVE BREAST CANCER;

EID: 84893129822     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S52600     Document Type: Article

References (186)

1. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23(29):7350-7360.
2. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721-1728.
3. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007;110(4): 876-884.
4. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009;113(2):357-370.
5. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012;23 Suppl 6:vi7-vi12.
6. Davis AA, Kaklamani VG. Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer. 2012; 2012:809291.
7. Hartley MC, McKinley BP, Rogers EA, et al. Differential expression of prognostic factors and effect on survival in young (, or =40) breast cancer patients: a case-control study. Am Surg. 2006;72(12):1189-1194.
8. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7(12):683-692.
9. Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20(7):1071-1082.
10. Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR. Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre-and postmenopausal women. Int J Cancer. 2002;98(1):118-127.
11. Gaudet MM, Press MF, Haile RW, et al. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat. 2011;130(2):587-597.
12. Dolle JM, Daling JR, White E, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1157-1166.
13. Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011;103(6):470-477.
14. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 2007;16(3):439-443.
15. Phipps AI, Chlebowski RT, Prentice R, et al. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(3):454-463.
16. Fagherazzi G, Chabbert-Buffet N, Fabre A, et al. Hip circumference is associated with the risk of premenopausal ER-/PR-breast cancer. Int J Obes (Lond). 2012;36(3):431-439.
17. Vona-Davis L, Rose DP, Hazard H, et al. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3319-3324.
18. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26(26):4282-4288.
19. Davison Z, de Blacquière GE, Westley BR, May FE. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia. 2011;13(6):504-515.
20. Maiti B, Kundranda MN, Spiro TP, Daw HA. The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat. 2010;121(2):479-483.
21. Amadou A, Hainaut P, Romieu I. Role of obesity in the risk of breast cancer: lessons from anthropometry. J Oncol. 2013;2013:906495.
22. Harris HR, Willett WC, Terry KL, Michels KB. Body fat distribution and risk of premenopausal breast cancer in the Nurses' Health Study II. J Natl Cancer Inst. 2011;103(3):273-278.
23. Ma H, Wang Y, Sullivan-Halley J, et al. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res. 2010;70(2):575-587.
24. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250-263.
25. Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L. Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomarkers Prev. 2011;20(9):1883-1891.
26. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-2795.
27. Hefti MM, Hu R, Knoblauch NW, et al. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res. 2013;15:R68.
28. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19(8):2334-2356.
29. De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res. 2003;9(3): 1039-1046.
30. Liedtke C, Hess KR, Karn T, et al. The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2013;138(2):591-599.
31. Zakhartseva LM, Gorovenko NG, Podolskaya SV, et al. Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations. Exp Oncol. 2009;31(3):174-178.
32. Rudat V, El-Sweilmeen H, Fadel E, et al. Age of 40 years or younger is an independent risk factor for locoregional failure in early breast cancer: a single-institutional analysis in Saudi Arabia. J Oncol. 2012; 2012:370385.
33. Suba Z. Circulatory estrogen level protects against breast cancer in obese women. Recent Pat Anticancer Drug Discov. 2013;8(2):154-167.
34. Suba Z, editor. Failures and controversies of the antiestrogen treatment of breast cancer. Estrogen Prevention for Breast Cancer. Hauppauge, New York: Nova Science Publishers Inc; 2013:105-125.
35. Bollet MA, Savignoni A, De Koning L, et al. Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment. Breast Cancer Res. 2009;11(4):R54.
36. Spratt JS, Meyer JS, Spratt JA. Rates of growth of human solid neoplasms: part I. J Surg Oncol. 1995;60:137-146.
37. Baer HJ, Colditz GA, Willett WC, Dorgan JF. Adiposity and sex hormones in girls. Cancer Epidemiol Biomarkers Prev. 2007;16(9): 1880-1888.
38. Stoll BA. Teenage obesity in relation to breast cancer risk. Int J Obes Relat Metab Disord. 1998;22(11):1035-1040.
39. Polson DW, Wadsworth J, Adams J et al. Polycystic ovaries: a common finding in normal women. Lancet. 1988;1:870-872.
40. Bloomgarden ZT. Second World Congress on the Insulin Resistance Syndrome: mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy. Diabetes Care. 2005;28(8):1821-1830.
41. Apter D, Vihko R. Endocrine determinants of fertility: serum androgen concentrations during follow-up of adolescents into the third decade of life. J Clin Endocrinol Metab. 1990;71(4):970-974.
42. Sturgeon SR, Potischman N, Malone KE, et al. Serum levels of sex hormones and breast cancer risk in premenopausal women: a case-control study (USA). Cancer Causes Control. 2004;15(1):45-53.
43. Suba Z. Common soil of smoking-associated and hormone-related cancers: estrogen deficiency. Oncol Rev. 2010;4:73-87.
44. Stamataki KE, Spina J, Rangou DB, Chlouverakis CS, Piaditis GP. Ovarian function in women with non-insulin dependent diabetes mellitus. Clin Endocrinol (Oxf). 1996;45(5):615-621.
45. Suba Z. Interplay between insulin resistance and estrogen deficiency as co-activators in carcinogenesis. Pathol Oncol Res. 2012;18(2):123-133.
46. Suba Z. Low estrogen exposure and/or defective estrogen signaling induces disturbances in glucose uptake and energy expenditure. J Diabet Metab. 272, doi.4172/2155-6156.1000272.
47. ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod. 2001;16(7):1527-1535.
48. Diamanti-Kandarakis E, Baillargeon J-P, Iuorno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab. 2003;88(5):1927-1932.
49. Deligeoroglou E, Michailidis E, Creatsas G. Oral contraceptives and reproductive system cancer. Ann N Y Acad Sci. 2003;997:199-208.
50. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. New Engl J Med. 2002;346:2025-2032.
51. Bernstein L, Lacey JV Jr. Receptors, associations and risk factor differences by breast cancer subtypes: positive or negative? J Natl Cancer Inst. 2011;103(6):451-453.
52. Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL, Palmer JR. Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. Cancer Epidemiol Biomarkers Prev. 2010;19(8):2073-2079.
53. Suba Z, editor. Discovery of estrogen deficiency as common cancer risk factor for highly and moderately estrogen dependent organs. Estrogen Prevention for Breast Cancer. Hauppauge, New York: Nova Science Publishers Inc; 2013:1-22.
54. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod. 2005;20: 2052-2060.
55. LaCroix AZ, Chlebowski RT, Manson JE, et al; WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305:1305-1314.
56. La Vecchia C, Negri E, Franceschi S, et al. Body mass index and postmenopausal breast cancer: an age specific analysis. Br J Cancer. 1997;75(3):441-444.
57. Rapp K, Schroeder J, Klenk J, et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia. 2006;49:945-952.
58. Colonna SV, Douglas Case L, Lawrence JA. A retrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor. Breast Cancer Res Treat. 2012;131(1): 325-331.
59. Amirikia KC, Mills P, Bush J, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer. 2011;117(12):2747-2753.
60. Reaven GM. Insulin resistance, cardiovascular disease, and the metabolic syndrome: How well do the emperor's clothes fit? Diabetes Care. 2004;27(4):1011-1012.
61. Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am J Pathol. 2006;169(5):1505-1522.
62. Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc Nutr Soc. 2012;71(1):181-189.
63. Rosato V, Bosetti C, Talamini R, Levi F, Negri E, La Vecchia C. [Metabolic syndrome and the risk of breast cancer]. Recenti Prog Med. 2011;102(12):476-478. Italian.
64. Healy LA, Ryan AM, Carroll P, et al. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol). 2010;22(4):281-288.
65. Kabat GC, Kim M, Chlebowski RT, et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2046-2053.
66. Sieri S, Muti P, Claudia A, et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer. 2012;130(4): 921-929.
67. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121(4):856-862.
68. Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr. 2007;86(3): s823-s835.
69. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol. 1998;51(7):581-586.
70. Schneider JG, Tompkins C, Blumenthal RS, Mora S. The metabolic syndrome in women. Cardiol Rev. 2006;14(6):286-291.
71. Donohoe CL, Doyle SL, Reynolds JV. Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr. 2011;3:12.
72. Rose DP, Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas. 2010;66(1):33-38.
73. Spangenburg EE, Wohlers LM, Valencia AP. Metabolic dysfunction under reduced estrogen levels: looking to exercise for prevention. Exerc Sport Sci Rev. 2012;40(4):195-203.
74. Potischman N, Swanson CA, Siiteri P, Hoover RN. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst. 1996;88(11):756-758.
75. Suba Z, Kásler M. Interactions of insulin and estrogen in the regulation of cell proliferation and carcinogenesis. Orv Hetil. 2012;153(4):125-136. Hungarian.
76. Morimoto LM, White E, Chen Z, et al. Obesity, body size and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control. 2002;13(8):41-51.
77. Ritte R, Lukanova A, Berrino F, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res. 2012;14:R76.
78. Huang Z, Willett WC, Colditz GA, et al. Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses' Health Study. Am J Epidemiol. 1999;150(12):1316-1324.
79. Franceschi S, Favero A, La Vecchia C, et al. Body size indices and breast cancer risk before and after menopause. Int J Cancer. 1996;67(2): 181-186.
80. Kotlyarevska K, Wolfgram P, Lee JM. Is waist circumference a better predictor of insulin resistance than body mass index in US adolescents? J Adolesc Health. 2011;49(3):330-333.
81. Sonnenschein E, Toniolo P, Terry MB, et al. Body fat distribution and obesity in pre-and postmenopausal breast cancer. Int J Epidemiol. 1999;28(6):1026-1031.
82. Connolly BS, Barnett C, Vogt KN, Li T, Stone J, Boyd NF. A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutr Cancer. 2002;44(2):127-138.
83. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev. 2003;4(3):157-173.
84. Rose DP, Vona-Davis L. Influence of obesity on breast cancer receptor status and prognosis. Expert Rev Anticancer Ther. 2009;9(8): 1091-1101.
85. Kwan ML, Kushi LH, Weltzien E, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009;11(3):R31.
86. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-a meta-analysis. Int J Cancer. 2009;124(3):698-712.
87. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL. Associations of Breast Cancer Risk Factors with Tumor Subtypes: A Pooled Analysis from the Breast Cancer Association Consortium Studies. J Natl Cancer Inst. 2011;103(3):250-263.
88. Amend K, Hicks D, Ambrosone CB. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res. 2006;66:8327-8330.
89. Stead LA, Lash TL, Sobieraj JE, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009;11(2):R18.
90. Stark A, Stapp R, Raghunathan A, et al. Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women. Breast Cancer Res Treat. 2012;131:561-570.
91. Holmes L Jr, Opara F, Hossain J. A five-year breast cancer-specific survival disadvantage of African American women. Afr J Reprod Health. 2010;14:195-200.
92. DeSantis C, Naishadham D, Jemal A. Cancer statistics for African Americans, 2013. CA Cancer J Clin. 2013;63(3):151-166.
93. Suba Z. Light deficiency confers breast cancer risk by endocrine disorders. Recent Pat Anticancer Drug Discov. 2012;7(3):337-344.
94. Otto S. Cancer epidemiology in Hungary and the Béla Johan National Program for the decade of health. Pathol Oncol Res. 2003;9:126-130.
95. Montag A, Kumar V. The female genital system and breast. In: Kumar V, Abbas AK, Fausto N, Mitchell RN, editors. Robbins Basic Pathology. 8th ed. Philadelphia, PA: Saunders Elsevier; 2007: 711-750.
96. Mousavi SM, Sundquist J, Hemminki K. Nasopharyngeal and hypopharyngeal carcinoma risk among immigrants in Sweden. Int J Cancer. 2010;127:2888-2892.
97. Hemminki K, Mousavi SM, Sundquist J, Brandt A. Does the breast cancer age at diagnosis differ by ethnicity? A study on immigrants to Sweden. Oncologist. 2011;16:146-154.
98. Viswanathan AN, Schernhammer ES. Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Lett. 2009;281:1-7.
99. Sánchez-Barceló EJ, Cos S, Mediavilla MD, Martínez-Campa C, González A, Alonso-González C. Melatonin-estrogen interactions in breast cancer. J Pineal Res. 2005;38:217-222.
100. Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the nurses' health study cohort. Cancer Epidemiol Biomarkers Prev. 2009;18(1):74-79.
101. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ. Estrogen signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev. 2006;30:118-128.
102. Gonzalez A, Cos S, Martinez-Campa C, et al. Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J Pineal Res. 2008;45:86-92.
103. Knower KC, To SQ, Takagi K, et al. Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts. Breast Cancer Res Treat. 2012;132(2):765-771.
104. Suba Z, editor. Insulin resistance, hyperinsulinemia and cancer risk. Estrogen Versus Cancer. Hauppauge, New York: Nova Science Publishers Inc.; 2009: 19-40.
105. Li S, Rosenberg L, Wise LA, Boggs DA, Lavalley M, Palmer JR. Age at natural menopause in relation to all-cause and cause-specific mortality in a follow-up study of US black women. Maturitas. 2013;75(3): 246-252.
106. Seo DC, Torabi MR. Racial/ethnic differences in body mass index, morbidity and attitudes toward obesity among US adults. J Natl Med Assoc. 2006;98(8):1300-1308.
107. Falkner B, Sherif K, Sumner A, Kushner H. Hyperinsulinism and sex hormones in young adult African Americans. Metabolism. 1999;48: 107-112.
108. Rose DP, Haffner SM, Baillargeon J. Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev. 2007;28:763-777.
109. Sarkissyan M, Wu Y, Vadgama JV. Obesity is associated with breast cancer in African-American women but not Hispanic women in South Los Angeles. Cancer. 2011;117:3814-3823.
110. Boucai L, Surks MI. Reference limits of serum TSH and free T4 are significantly influenced by race and age in an urban outpatient medical practice. Clin Endocrinol (Oxf). 2009;70:788-793.
111. Vriend J, Bertalanffy FD, Ralcewicz TA. The effects of melatonin and hypothyroidism on estradiol and gonadotropin levels in female Syrian hamsters. Biol Reprod. 1987;36:719-728.
112. Bellipanni G, Bianchi P, Pierpaoli W, Bulian D, Ilyia E. Effects of melatonin in perimenopausal women and menopausal women: a randomized and placebo controlled study. Exp Gerontol. 2001;36: 297-310.
113. Kuijpens JL, Nyklíctek I, Louwman MW, Weetman TA, Pop VJ, Coebergh JW. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid. 2005;15:1253-1259.
114. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control. 2005;16:83-95.
115. Harris SS. Does vitamin D deficiency contribute to increased rates of cardiovascular disease and type 2 diabetes in African Americans? Am J Clin Nutr. 2011;93:1175S-1178S.
116. Grant WB, Peiris AN. Possible role of serum 25-hydroxyvitamin D in black-white health disparities in the United States. J Am Med Dir Assoc. 2010;11:617-628.
117. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171-182.
118. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434: 917-921.
119. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med (Berl). 2006;84: 16-28.
120. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310-2318.
121. Lee E, McKean-Cowdin R, Ma H, et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol. 2011;29(33): 4373-4380.
122. Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci U S A. 2001;98(17):9587-9592.
123. Fan S, Ma YX, Wang C, et al. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene. 2001;20(1): 77-87.
124. Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol. 2010;28(2):240-244.
125. Lin WT, Beattie M, Chen LM, et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer. 2013;119(9):1652-1659.
126. Finch A, Valentini A, Greenblatt E, et al; Hereditary Breast Cancer Study Group. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril. 2013;99(6):1724-1728.
127. Kim J, Oktay K. Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention? Cancer Causes Control. 2013;24(3):421-426.
128. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331:1056-1061.
129. McLaughlin JR, Risch HA, Lubinski J, et al; Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 2007;8(1):26-34.
130. Antoniou AC, Rookus M, Andrieu N, et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev. 2009;18(2):601-610.
131. Whittemore AS, Balise RR, Pharoah PD, et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer. 2004;91(11):1911-1915.
132. Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther. 2011;11(8):1197-1207.
133. Milne RL, Knight JA, John EM, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev. 2005;14(2):350-356.
134. Adlercreutz HJ. Phytoestrogens and breast cancer. J Steroid Biochem Mol Biol. 2002;83(1-5):113-118.
135. Cabanes A, Wang M, Olivo S, et al. Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis. Carcinogenesis. 2004;25(5):741-748.
136. Suba Z. Beneficial role of estrogen signaling in glucose homeostasis and energy expenditure. In: Johnson CC, Williams DB, editors. Glucose Uptake: Regulation, Signaling Pathways and Health Implications. Hauppauge, New York: Nova Science Publishers Inc; 2013.
137. Bordeleau L, Lipscombe L, Lubinski J, et al; Hereditary Breast Cancer Clinical Study Group. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer. 2011;117(9):1812-1818.
138. Kotsopoulos J, Olopado OI, Ghadirian P, et al. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2005;7(5):R833-R843.
139. Key TJ. Hormones and cancer in humans. Mutat Res. 1995;333(1-2): 59-67.
140. den Tonkelaar I, de Waard F. Regularity and length of menstrual cycles in women aged 41-46 in relation to breast cancer risk: results from the DOM-project. Breast Cancer Res Treat. 1996;38(3):253-258.
141. Wolpert BJ, Amr S, Ezzat S, et al. Estrogen exposure and bladder cancer risk in Egyptian women. Maturitas. 2010;67(4):353-357.
142. Teras LR, Patel AV, Rodriguez C, Thun MJ, Calle EE. Parity, other reproductive factors, and risk of pancreatic cancer mortality in a large cohort of US women (United States). Cancer Causes Control. 2005;16(9):1035-1040.
143. Bosetti C, Negri E, Franceschi S, Conti E, Levi F, Tomei F. Risk factors for oral and pharyngeal cancer in women: a study from Italy and Switzerland. Br J Cancer. 2000;82(1):204-207.
144. Britt K, Ashworth A, Smalley M. Pregnancy and the risk of breast cancer. Endocr Relat Cancer. 2007;14(4):907-933.
145. Källén B, Finnström O, Lindam A, Nilsson E, Nygren KG, Olausson PO. Malignancies among women who gave birth after in vitro fertilization. Hum Reprod. 2011;26(1):253-258.
146. Lai YC, Hamazaki K, Yoshizawa K, et al. Short-term pregnancy hormone treatment of N-methyl-N-nitrosourea-induced mammary carcinogenesis in relation to fatty acid composition of serum phospholipids in female Lewis rats. In Vivo. 2010;24(4):553-560.
147. Holcomb VB, Hong J, Núñez NP. Exogenous estrogen protects mice from the consequences of obesity and alcohol. Menopause. 2012;19(6):680-690.
148. Rajkumar L, Kittrell FS, Guzman RC, Brown PH, Nandi S, Medina D. Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models. Breast Cancer Res. 2007;9(1):R12.
149. Hong J, Holcomb VB, Kushiro K, Núñez NP. Estrogen inhibits the effects of obesity and alcohol on mammary tumors and fatty liver. Int J Oncol. 2011;39(6):1443-1453.
150. Nkhata KJ, Ray A, Dogan S, Grande JP, Cleary MP. Mammary tumor development from T47-D human breast cancer cells in obese ovariectomized mice with and without estradiol supplements. Breast Cancer Res Treat. 2009;114(1):71-83.
151. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer. 2008;113(7):1521-1526.
152. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109(1):123-139.
153. Xing P, Li J, Jin F. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol. 2010;27(3):926-931.
154. Velentgas P, Daling JR. Risk factors for breast cancer in younger women. J Natl Cancer Inst Monogr. 1994;(16):15-24.
155. Opdahl S, Alsaker MD, Janszky I, Romundstad PR, Vatten LJ. Joint effect of nulliparity and other breast cancer risk factors. Br J Cancer. 2011;105(5):731-736.
156. Newcomb PA, Trentham-Dietz A, Hampton JM, et al. Late age at full term birth is strongly associated with lobular breast cancer. Cancer. 2011;117(9):1946-1956.
157. Tsubura A, Uehara N, Matsuoka Y, Yoshizawa K, Yuri T. Estrogen and progesterone treatment mimicking pregnancy for protection from breast cancer. In Vivo. 2008;22(2):191-201.
158. Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol. 2005;19:833-842.
159. Segars JH, Driggers PH. Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes. Trends Endocrinol Metab. 2002;13:349-354.
160. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997;82:4258-4265.
161. Nilsson S, Mäkelä S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev. 2001;81:1535-1565.
162. Lindberg MK, Movérare S, Skrtic S, et al. Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a "ying yang" relationship between ERalpha and ERbeta in mice. Mol Endocrinol. 2003;17:203-208.
163. Shyamala G, Ferenczy A. The nonresponsiveness of lactating mammary gland to estradiol. Endocrinol. 1982;110:1249-1256.
164. Lindberg BS, Johansson ED, Nilsson BA. Plasma levels of nonconjugated oestrone, oestradiol-17beta and oestriol during uncomplicated pregnancy. Acta Obstet Gynecol Scand Suppl. 1974;32:21-36.
165. Sivaraman L, Stephens LC, Markaverich BM, et al. Hormone-induced refractoriness to mammary carcinogenesis in Wistar-Furth rats. Carcinogenesis. 1998;19(9):1573-1581.
166. Grubbs CJ, Juliana MM, Whitaker LM. Short-term hormone treatment as a chemopreventive method against mammary cancer initiation in rats. Anticancer Res. 1988;8(1):113-117.
167. Leick MB, Jordan VC. Evolution of estrogen action in breast cancer: from culprit to killer. In: Suba Z, editor. Estrogen Prevention for Breast Cancer.-Hauppauge, New York: Nova Science Publishers Inc; 2012: 127-149.
168. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer. Cancer Res. 1988;48:246-253.
169. Marquez DC, Pietras RJ. Membrane-associated binding sites for estrogen contribute to growth regulation in human breast cancer cells. Oncogene. 2001;20:5420-5430.
170. Pietras RJ, Arboleda J, Wongvipat N, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone independent growths in human breast cancer cells. Oncogene. 1995;10: 2435-2446.
171. Lundholt BK, Briand P, Lykkesfeldt AE. Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat. 2001;67:199-214.
172. Stoica A, Saceda M, Doraiswamy VL, Coleman C, Martin MB. Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. J Endocrinol. 2000;165(2):371-378.
173. Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids. 2007;72:135-143.
174. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer. 2006;13 Suppl 1:S15-S24.
175. Ingle JN. Estrogen as therapy for breast cancer. Breast Cancer Res. 2002;4:133-136.
176. Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971;25(2):270-275.
177. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981;304(1):16-21.
178. Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol. 2008;26:798-805.
179. Hayes DF. Tamoxifen: Dr Jekyll and Mr Hyde? J Natl Cancer Inst. 2004;96:895-897.
180. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609-1618.
181. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col FN. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18:937-947.
182. Lønning PE. Additive endocrine therapy for advanced breast cancer back to the future. Acta Oncol. 2009;48:1092-1101.
183. Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA. 2009;302:774-780.
184. Jordan VC, Ford LG. Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis. Cancer Prev Res (Phila). 2011;4(5):633-637.
185. Maximov PY, Lewis-Wambi JS, Jordan VC. The paradox of oestradiol-induced breast cancer cell growth and apoptosis. Curr Signal Transduct Ther. 2009;4(2):88-102.
186. Lewis-Wambi JS, Jordan VC. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res. 2009;11(3):206.